European journal of preventive cardiology最新文献

{"title":"Unsupervised Home-Based Isometric Exercise Training in HFpEF: Some Notes of Optimism and a Word of Caution.","authors":"Marco Guazzi","doi":"10.1093/eurjpc/zwaf641","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf641","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"The Presence or Absence of Standard Modifiable Cardiovascular Risk Factors in Patients with Myocardial Infarction Impacts Long-Term but not 30-Day Mortality: a UK Biobank Prospective Cohort Study\" - Authors' Reply.","authors":"Wen Kai Wong","doi":"10.1093/eurjpc/zwaf638","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf638","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the SAFEHEART risk-equation for predicting cardiovascular events in Australian patients with familial hypercholesterolaemia.","authors":"María Elena Mansilla-Rodríguez, Manuel Jesús Romero-Jiménez, Jing Pang, Dick C Chan, Eva Nadiejda Gutiérrez-Cortizo, Pedro Mata, José Luis Sánchez-Ramos, Gerald F Watts","doi":"10.1093/eurjpc/zwaf631","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf631","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term impact of telemedicine for lipid control after an acute coronary syndrome.","authors":"César Jiménez-Méndez, Rafael Vázquez-García, William Delgado, Daniel Bartolome, Etel Silva","doi":"10.1093/eurjpc/zwaf630","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf630","url":null,"abstract":"<p><strong>Aims: </strong>Lipid control is a pivotal measure for secondary prevention following an acute coronary syndrome (ACS). However, current registries indicate that only a small proportion of patients achieve the target LDL cholesterol (LDL-c) levels. Telemedicine is increasingly used, particularly in post-ACS management. We aimed to assess the long-term impact of a telemedicine-based strategy for lipid control following ACS.</p><p><strong>Methods: </strong>This prospective study consecutively enrolled patients with ACS. All patients were discharged on high-intensity statins, and their lipid profiles were assessed one month later. At that point, patients were contacted by phone, and treatment was adjusted according to the therapeutic algorithm of the Spanish Society of Cardiology. Follow-up calls continued monthly until LDL-c <55 mg/dL was achieved.</p><p><strong>Results: </strong>A total of 344 patients (mean age 67.3±12.4years, 32%women) were included. Baseline LDL-c was 108.4±40.7mg/dL, decreasing to 48.7 ± 14.4 mg/dL post-intervention. LDL-c <55mg/dL was achieved in 82.6% of patients, with an average treatment optimization time of 3.2±2.1 months. After a median follow-up of 39±10 months, 43 patients (12.5%) had died, and 72 (20.9%) experienced a 4P-MACE event. In multivariate analysis, LDL-c at the end of follow-up was independently associated with higher cardiovascular mortality (HR 1.04, 95%CI 1.01-1.08, p0.024), along with age (HR 1.09, 95%CI 1.02-1.16, p0.004) and previous coronary artery disease (HR 4,21 95%CI 1.18-14.9, p0.02).</p><p><strong>Conclusion: </strong>A telemedicine-based intensive lipid-lowering strategy effectively optimized LDL-c levels and was associated with reduced cardiovascular mortality in a high-risk secondary prevention cohort.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic utility of the Global Leadership Initiative on Sarcopenia model in older patients with heart failure: post-hoc analysis of the FRAGILE-HF study.","authors":"Taisuke Nakade, Daichi Maeda, Yuya Matsue, Nobuyuki Kagiyama, Yudai Fujimoto, Tsutomu Sunayama, Taishi Dotare, Kentaro Jujo, Kazuya Saito, Kentaro Kamiya, Hiroshi Saito, Yuki Ogasahara, Emi Maekawa, Masaaki Konishi, Takeshi Kitai, Kentaro Iwata, Hiroshi Wada, Takatoshi Kasai, Hirofumi Nagamatsu, Shin-Ichi Momomura, Tohru Minamino","doi":"10.1093/eurjpc/zwaf636","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf636","url":null,"abstract":"<p><strong>Aims: </strong>The Global Leadership Initiative on Sarcopenia (GLIS) defines sarcopenia based on muscle mass, muscle strength, and muscle-specific strength, considering physical performance as an outcome rather than a diagnostic criterion. This study aimed to evaluate whether the GLIS model can effectively assess the prognostic value and impaired physical performance in older patients with heart failure. A post-hoc analysis of the FRAGILE-HF study, a multicentre prospective observational cohort study, was conducted.</p><p><strong>Methods: </strong>The analysis included 891 patients (median age: 81 [interquartile range: 74-86] years; 41.9% women) hospitalized for heart failure. Sarcopenia and possible sarcopenia were assessed using the GLIS model. The primary outcome was 2-year all-cause mortality, and the secondary outcome was impaired physical performance, including 6-minute walk distance.</p><p><strong>Results: </strong>According to the GLIS model, sarcopenia and possible sarcopenia were observed in 186 (20.9%) and 539 (60.5%) patients, respectively. Sarcopenia was associated with significantly increased 2-year mortality (adjusted hazard ratio 3.38, 95% confidence interval [CI] 1.74-6.56, P < 0.001). Sarcopenia and possible sarcopenia were significantly associated with impaired physical performance. The diagnosis of sarcopenia based on the GLIS model provided superior prognostic discrimination compared to the diagnosis based on the conventional Asian Working Group for Sarcopenia 2019 model (net reclassification improvement 0.269, 95% CI 0.141-0.397, P < 0.001).</p><p><strong>Conclusion: </strong>The diagnosis of sarcopenia based on the GLIS model was associated with prognosis and impaired physical performance in older patients with heart failure.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social determinants of health in cancer survivors and the risk of cardiovascular events.","authors":"Shunxuan Yan, Yingsi Hu, Weiwen Su, Shangxi Xie, Jialing Lin, Jinfeng Ding, Jinqiu Yuan, Jiali Feng, Qiangsheng He, Da-Lin Lu, Yanhui Gao, Xiwen Qin","doi":"10.1093/eurjpc/zwaf633","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf633","url":null,"abstract":"<p><strong>Aims: </strong>The impact of social determinants of health (SDoH) on cardiovascular disease (CVD) risk in cancer survivors remains unclear. We examined the association between SDoH and subsequent CVD risk among cancer survivors.</p><p><strong>Methods: </strong>This retrospective cohort study included 18,992 cancer survivors and 75,968 propensity score-matched non-cancer controls from the UK Biobank. A composite SDoH score was generated using 17 components across 5 domains, classifying participants into favorable, medium, and unfavorable SDoH groups. Cox models were used to assess associations between SDoH and incident CVD, including ischemic heart disease (IHD), heart failure (HF), stroke, and CVD mortality.</p><p><strong>Results: </strong>Compared with cancer survivors with favorable SDoH, those with medium and unfavorable SDoH had higher CVD risks: hazard ratio (HR) 1.17 (95% CI: 1.09-1.27) and HR 1.32 (95% CI: 1.23-1.43), respectively. Unfavorable SDoH was also associated with increased risk of IHD (HR: 1.31; 95% CI: 1.15-1.49), HF (HR: 1.58; 95% CI: 1.30-1.92), stroke (HR: 1.47; 95% CI: 1.18-1.84), and CVD mortality (HR: 1.54; 95% CI: 1.25-1.90). Cancer survivors with favorable SDoH had overall CVD risks similar to matched non-cancer controls (HR: 1.07; 95% CI: 1.00-1.13). In joint analysis, cancer survivors with favorable SDoH had a higher risk (HR: 1.22; 95% CI, 1.15-1.28) than their non-cancer counterparts.</p><p><strong>Conclusion: </strong>Among cancer survivors, unfavorable SDoH were associated with elevated CVD risk, whereas favorable SDoH attenuated this risk to levels comparable with non-cancer population. That may partly reflect the increased risk observed among non-cancer with unfavorable SDoH. Targeted interventions and policy measures addressing social determinants are needed to mitigate cardiovascular disparities in cancer survivorship.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Neutrophil-to-Lymphocyte Ratio With Clinical Outcomes After Percutaneous Coronary Intervention.","authors":"Angelo Oliva, Birgit Vogel, Samantha Sartori, Davide Cao, Kenneth F Smith, Benjamin Bay, Joseph Sweeny, Francesca M Di Muro, Mary Danias, Pedro Moreno, Mauro Gitto, Giulio G Stefanini, Stuart J Pocock, Deepak L Bhatt, George Dangas, Paul M Ridker, Annapoorna Kini, Samin Sharma, Roxana Mehran","doi":"10.1093/eurjpc/zwaf597","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf597","url":null,"abstract":"<p><strong>Background: </strong>Inflammation contributes significantly to coronary artery disease (CAD). The neutrophil-to-lymphocyte ratio (NLR) has emerged as a readily available biomarker reflecting both inflammatory and immune cells' activity, potentially enhancing risk stratification of patients with CAD. This study evaluates the clinical impact of baseline NLR in patients undergoing percutaneous coronary intervention (PCI) for both chronic coronary syndrome (CCS) and acute coronary syndrome (ACS).</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients undergoing PCI at Mount Sinai Hospital between 2012 and 2022. Patients were stratified into NLR quartiles and outcomes were analyzed using Cox regression models. The primary endpoint was major adverse cardiovascular events (MACE) at 1-year follow-up, including all-cause death, myocardial infarction (MI), and stroke.</p><p><strong>Results: </strong>A total of 7,287 patients were included in the study. Age, male sex, comorbidities, hsCRP and complexity of PCI tended to be higher in the highest NLR quartiles. At 1-year, MACE incidence increased across NLR quartiles, from 5.1% (1st quartile) to 9.3% (4th quartile) (P for trend = 0.004). Compared with the 1st quartile, the 4th NLR quartile (NLR >5.0) was associated with increased adjusted risks of MACE (adjHR 1.52, 95% CI 1.12-2.05), all-cause death (adjHR 1.71, 95% CI 1.10-2.65), MI (adjHR 1.53, 95% CI 1.00-2.35), and bleeding (adjHR 2.01, 95% CI 1.50-2.70). Ischemic risk associated with high NLR was more pronounced in patients presenting with ACS and chronic kidney disease (CKD).</p><p><strong>Conclusions: </strong>Baseline NLR is associated with adverse cardiovascular outcomes in CAD patients undergoing PCI. Assessment of NLR could enhance risk stratification particularly in patients with ACS and CKD.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Sensitivity C-Reactive Protein (hsCRP): Just Measure It!","authors":"Paul M Ridker","doi":"10.1093/eurjpc/zwaf624","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf624","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation in the Spotlight: Neutrophil-to-Lymphocyte Ratio Takes Centre Stage in Atherosclerotic Cardiovascular Disease.","authors":"Angelo Laino, Antonio Pio Vitale, Raffaele Piccolo","doi":"10.1093/eurjpc/zwaf606","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf606","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Elevated High-Sensitivity C-Reactive Protein Levels in Individuals with Atherosclerotic Cardiovascular Disease in the US and the UK.","authors":"Kausik K Ray, Simon Bertram Reuter, Aysegul Dalbeler, Mads D Faurby, Gasper Letnar, Jimmi Mathisen, Michael G Nanna, Fu Siong Ng, Jonathan Pearson-Stuttard, Naveed Sattar, Andrew Thompson, Ann Marie Navar","doi":"10.1093/eurjpc/zwaf609","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf609","url":null,"abstract":"<p><strong>Aim: </strong>Novel therapies are under evaluation for upstream inhibition of inflammatory pathways in atherosclerotic cardiovascular disease (ASCVD). Elevated high-sensitivity C-reactive protein (hsCRP) is a downstream marker of these pathways but is not routinely measured. We aimed to identify potential factors associated with elevated hsCRP.</p><p><strong>Methods: </strong>This cross-sectional study included individuals with ASCVD from the UK Biobank (2006-2010) and the US National Health and Nutrition Examination Survey (NHANES; 1999-2010 and 2015-2018). Factors associated with elevated hsCRP (2-10 mg/L) were evaluated using multivariable logistic regression.</p><p><strong>Results: </strong>Six factors were associated with greater odds of elevated hsCRP in both cohorts (UK Biobank n = 23,045; NHANES n = 3,415): obesity (UK Biobank odds ratio [OR] [95% confidence interval (CI)]: 3.48 [3.18-3.80]); NHANES 4.11 [2.66-6.34]), overweight (1.56 [1.44-1.70]; 2.26 [1.51-3.38]), being a current smoker (2.47 [2.27-2.69]; 1.96 [1.23-3.10]), female sex (1.69 [1.59-1.80]; 1.69 [1.24-2.31]), and increased low-density lipoprotein cholesterol (1.05 [1.04-1.06]; 1.00 [1.00-1.00], per 10 mg/dL increase) and triglyceride levels (1.01 [1.01-1.01]; 1.00 [1.00-1.00], per 10 mg/dL increase) (all p <0.05). Receiving statins was associated with lower odds in both cohorts (UK Biobank OR [95% CI] 0.69 [0.64-0.75]; NHANES 0.54 [0.39-0.74]). When these factors, plus chronic kidney disease stage G3-5, were considered in combination, hsCRP levels were higher in individuals with more factors (median hsCRP with seven factors: UK Biobank 5.39 mg/L; NHANES 6.99 mg/L).</p><p><strong>Conclusions: </strong>The factors identified may support data-driven targeted testing to identify those most likely to have elevated hsCRP, who could potentially benefit from emerging anti-inflammatory therapies.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}